Since 2015, eleven new brands have launched in the Parkinson’s disease (PD) therapy market (e.g., Inbrija [Acorda], Kynmobi [Sunovion], Ongentys [Neurocrine]), and several more are on the horizon…
Parkinson’s disease is a chronic neurodegenerative disease characterized by progressively worsening motor symptoms. Treatment of Parkinson’s disease in China comprises a broad range of…
Core to Parkinson’s disease (PD) treatment is the co-prescription of various formulations of the gold-standard SOC levodopa with a range of adjunctive therapies from other drug classes (e.g.,…
Since 2015, eleven new brands have launched in the Parkinson’s disease (PD) therapy market (e.g., Inbrija [Acorda], Kynmobi [Sunovion], Ongentys [Neurocrine]), and several more are on the horizon…
Since 2015, eight new brands have launched into the highly generic U.S. Parkinson’s disease (PD) therapy market, and six more are expected to launch soon. Chronic polypharmacy and progressive…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key Parkinson's disease patient populations covering 171 countries…
MARKET OUTLOOK Parkinson’s disease (PD) is a progressive neurodegenerative condition that is treated chronically with prescription therapies from an array of mechanistically distinct drug…
Since 2015, the genericized Parkinson’s disease (PD) market has witnessed the launch of nearly a dozen unique brands (e.g., Inbrija, Kynmobi, Nourianz), and several more are on the horizon,…
For the abstract please provide an overview paragraph here and then fill in the bulleted sections below. Feel free to modify the bulleted section. Leverage content from a brochure if you have one…
The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ABBV-951, IPX203); two…
Parkinson’s disease (PD) is widely recognized as a motor disorder, but PD is also associated with a diverse set of nonmotor symptoms. Surveyed neurologists estimate that 20% of their PD patients…
The Parkinson’s disease (PD) therapy market is changing: the first new levodopa formulation (Rytary) in over a decade launched in 2015 and more are on the horizon (e.g., ND0612, IPX203); two…
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment approach can be…
DRG Epidemiology's coverage of Parkinson's disease (PD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…
DRG Epidemiology's coverage of Parkinson's disease (PD) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and…